title: Pharmacokinetics of (Me)Arg-Lys-Pro-Trp-tert-Leu-Leu-OEt and (Me)Arg-Lys-Pro-Trp-tert-Leu-Leu administered intravenously to beagle dogs.
abstract: The pharmacokinetics of two analogues (NT-1 and NT-2) of the smallest active fragment of neurotensin were investigated in beagle dogs after intravenous (iv) administration at the doses of 0.1 and 0.5 mg/kg for NT-1 and of 0.25 and 0.5 mg/kg for NT-2. After iv administration of these two drugs, the plasma levels decreased with time with a biexponential pattern, and linear kinetic behavior was observed. The pharmacokinetic parameters (mean +/- standard error of mean) after iv administration of NT-1 at 0.1 mg/kg were as follows: the half-life of the distribution phase (t1/2 alpha) was 0.29 +/- 0.11 h, the half-life of the terminal phase (t1/2 beta) was 1.99 +/- 0.41 h, total plasma clearance (CL) was 33.2 +/- 6.3 mL/h/kg, steady-state volume of distribution (Vdss) was 57.1 +/- 2.8 mL/kg, and mean residence time (MRT) was 2.20 +/- 0.55 h. The t1/2 alpha, t1/2 beta, CL, Vdss, and MRT values after iv administration of NT-2 at 0.25 mg/kg were 0.11 +/- 0.02 h, 0.58 +/- 0.04 h, 257.3 +/- 17.2 mL/h/kg, 180.3 +/- 4.6 mL/kg, and 0.71 +/- 0.04 h, respectively. After iv administration of NT-1, NT-2 was detected in the plasma. It was confirmed from this result that NT-1 was metabolically hydrolyzed to NT-2 in the body of beagle dog.
authors.affiliation: Tsukuba Research Laboratories, Eisai Company, Ltd., Ibaraki, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Tokumura
authors.forename: R
authors.initials: R
authors.lastname: Machida
authors.forename: Y
authors.initials: Y
authors.lastname: Tsuchiya
authors.forename: A
authors.initials: A
authors.lastname: Sasaki
authors.forename: K
authors.initials: K
authors.lastname: Abe
authors.forename: T
authors.initials: T
authors.lastname: Tanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Saeki
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001798:Blood Proteins / Q000378:metabolism; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D004285:Dogs; D006207:Half-Life; D007275:Injections, Intravenous; D008297:Male; D008969:Molecular Sequence Data; D009496:Neurotensin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D009842:Oligopeptides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011485:Protein Binding
chemical_list: D001798:Blood Proteins; D009842:Oligopeptides; D010446:Peptide Fragments; C068951:methyl(arginyl)-lysyl-prolyl-tryptophyl-tert-leucyl-leucine; C068195:methylarginyl-lysyl-prolyl-tryptophyl-tert-leucyl-leucyl-ethyl ester; D009496:Neurotensin